The cGAS pathway is normally activated when DNA appears in the wrong cellular compartment. In healthy cells, most DNA is confined to the nucleus and mitochondria. DNA fragments released during infection, cellular stress or tissue damage can instead accumulate in the cytoplasm, where cGAS binds them and produces the signalling molecule cyclic GMP–AMP. This molecule activates the adaptor protein STING, which then triggers a cascade of kinases and transcription factors, including IRF3 and NF-κB. The result is production of type I interferons and other inflammatory mediators. That response is valuable against certain pathogens, but excessive or chronically activated signalling can disrupt tissue function. The new work suggests that in the intestine, this defensive circuitry has consequences far beyond local immunity, influencing the metabolic conversation between the gut microbiota and adipose tissue.

The researchers found evidence that intestinal cGAS signalling is heightened in obesity. Their analysis indicated activation of the pathway in intestinal samples from humans with obesity and in male mice exposed to a high-calorie diet. Increased signalling was accompanied by greater expression of type I interferons and signs of heightened immune activity among intestinal cells. Type I interferons are powerful antiviral cytokines that change gene expression across many cell types, preparing tissues to respond to infection. However, persistent interferon activity can also reshape epithelial biology, alter interactions with resident microbes and affect the production or handling of small molecules generated in the gut. The observations do not suggest that cGAS is the sole cause of obesity, but they identify it as a potentially important biological response to the intestinal stress associated with excess nutrition.

To test whether the pathway was merely correlated with obesity or actively contributed to it, the investigators deleted the cGAS gene in intestinal epithelial cells. These cells form the gut lining and represent a critical interface between food, microbes and the immune system. They absorb nutrients, maintain the intestinal barrier and release signals that influence organs elsewhere in the body. Mice lacking cGAS in this compartment were protected from diet-induced weight gain despite consuming an obesity-promoting diet. The animals also showed increased energy expenditure, meaning they used more energy over time rather than simply absorbing fewer calories. Their metabolic profiles improved as well, indicating benefits that extended beyond body weight. Because cGAS was removed selectively from the intestinal epithelium, the results highlight the gut lining as a signalling hub rather than implying that global inhibition of cGAS would produce the same effects.

The mechanism depended on the gut microbiota, the dense community of microorganisms that transforms dietary compounds and releases metabolites into the intestinal environment and circulation. When the researchers disrupted or altered the microbiota, the protective metabolic effects of intestinal cGAS deletion were diminished. This finding places bacteria between the intestinal immune sensor and the body’s energy-burning machinery. The study identified Lactobacillus murinus as a particularly important member of this microbial network. In the absence of intestinal epithelial cGAS, the abundance or activity of this bacterium was associated with increased production of indole-3-acetic acid, commonly known as IAA. IAA is an indole-derived metabolite generated from tryptophan by microbial metabolism. Although it is chemically related to plant auxins, in mammals it can act as a signalling molecule capable of influencing immune and metabolic pathways.

According to the study, IAA was a key messenger in the gut-to-adipose effect. The metabolite promoted thermogenesis, the process by which specialized fat cells convert stored chemical energy into heat. This function is most strongly associated with brown and beige adipose tissue, where mitochondria contain uncoupling protein 1, or UCP1. UCP1 dissipates the proton gradient normally used to generate ATP, releasing energy as heat instead. Increased thermogenesis raises total energy expenditure and can counter the accumulation of fat during excess caloric intake. The findings suggest that intestinal cGAS–STING–interferon activity suppresses this beneficial microbial output, while removing cGAS allows an L. murinus–IAA axis to become more active and stimulate heat-producing fat. In this model, an immune signal in the intestine changes microbial chemistry, and that chemistry alters the behaviour of adipose tissue.

The study’s implications extend beyond a simple relationship between inflammation and weight gain. The intestine must continuously distinguish harmless dietary and microbial signals from genuine danger, and cGAS is part of the molecular machinery that makes those judgements. Nutrient overload, epithelial stress and changes in microbial communities may increase the amount of DNA or DNA-like material sensed by the pathway, producing interferon responses that are appropriate in some circumstances but metabolically costly when sustained. By reducing the availability of IAA, chronic intestinal cGAS activity could weaken thermogenic capacity and favour energy storage. This proposed circuit offers a possible explanation for how local immune activation contributes to systemic metabolic disease without requiring inflammation to begin in adipose tissue itself.

The researchers caution, however, that the findings currently provide a stronger mechanistic case in male mice than in humans. The human observations show that intestinal cGAS signalling is activated in people with obesity, but they do not establish that blocking the pathway would cause weight loss or improve metabolic disease in patients. Sex, age, diet, genetics and the composition of the microbiota could all affect the pathway, and the study’s central animal experiments were conducted in males. IAA is also not a universal therapeutic answer: its effects may depend on dose, tissue exposure, receptor signalling and the wider microbial community in which it is produced. Manipulating L. murinus or administering IAA would require careful testing for safety, durability and unintended effects on immunity.

Even with those limitations, the work identifies a striking therapeutic concept: treating obesity by rewiring an immune–microbial–metabolic circuit in the intestine. Future strategies could seek to inhibit cGAS or STING selectively in intestinal epithelial cells, temper excessive type I interferon signalling, support beneficial microbial producers of IAA or deliver metabolites that enhance adipose thermogenesis. Such approaches would need to preserve the essential infection-fighting functions of cGAS while avoiding systemic immune suppression. The study by Deng, Meng, Yang and colleagues therefore adds the intestinal lining to the growing list of tissues that can control whole-body energy balance. It also reinforces a broader lesson of modern metabolic biology: the route to healthier fat may begin not in fat itself, but in the molecular dialogue between gut cells and the microbes living alongside them.

Subject of Research: Intestinal cGAS–STING–type I interferon signalling, gut microbiota, indole-3-acetic acid and obesity-related energy metabolism.

Article Title: Intestinal cGAS–STING–IFN signalling promotes obesity by downregulating microbiota-derived IAA in male mice.

Article References: Deng, J., Meng, W., Yang, Y. et al. “Intestinal cGAS–STING–IFN signalling promotes obesity by downregulating microbiota-derived IAA in male mice.” Nature Metabolism 8, 1713–1729 (2026). https://doi.org/10.1038/s42255-026-01562-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01562-4

Keywords: cGAS, STING, type I interferon, intestinal epithelium, obesity, gut microbiota, Lactobacillus murinus, indole-3-acetic acid, IAA, adipose thermogenesis, energy expenditure.

Antibiotic use in infants has long been a double-edged sword in pediatric care. While these powerful agents are indispensable for combating bacterial infections, their indiscriminate impact on the developing gut microbiota has raised concerns. The study, conducted by Heyman et al., utilized large-scale real-world data spanning several years, capturing the antibiotic exposure profiles of thousands of infants and tracking their growth patterns through childhood into adolescence. This longitudinal approach provided unprecedented insights into how early microbial disruptions might predispose individuals to overweight and obesity, phenomena that continue to escalate at alarming rates worldwide.

Central to this investigation is the concept of microbial dysbiosis—a state characterized by reduced microbial diversity and altered community structure in the gut. Infancy represents a critical window for the establishment of a stable and functionally resilient microbiome, which co-evolves with the host immune system and metabolism. Antibiotics administered during this vulnerable period can inadvertently deplete beneficial bacterial populations, impede colonization by protective species, and foster an ecological niche favorable to opportunistic pathogens. These microbial imbalances are hypothesized to impair the metabolic programming of the host, influencing energy harvest from diet, fat storage mechanisms, and inflammatory pathways.

The researchers meticulously identified antibiotic exposure through medical records, categorizing usage by timing, frequency, and class of antibiotics administered. They then correlated these variables with body mass index (BMI) measurements and the prevalence of overweight status as defined by pediatric growth charts. Their statistical models accounted for confounders such as birth weight, socioeconomic factors, breastfeeding duration, and maternal health indicators, ensuring robust adjustment for potential biases. The results revealed a consistent association: infants exposed to antibiotics, especially during the first six months of life, exhibited significantly higher odds of becoming overweight during both childhood and adolescence.

Delving deeper into mechanistic insights, the study highlighted how certain antibiotic classes, notably broad-spectrum agents, exert more pronounced disturbances on the gut microbiota than narrow-spectrum antibiotics. Broad-spectrum antibiotics, by targeting a wider array of bacterial taxa, may engender a more profound depletion of key commensal organisms involved in nutrient metabolism and immunomodulation. These perturbations have been linked to shifts in gene expression pathways related to energy homeostasis. For instance, alterations in the production of short-chain fatty acids (SCFAs), critical metabolites generated by bacterial fermentation, could modulate hunger signaling and adipocyte differentiation, thereby influencing weight gain trajectories.

The implications of this research extend beyond clinical decision-making in pediatrics. It invites a re-evaluation of antibiotic stewardship paradigms, emphasizing the necessity of judicious prescribing practices that carefully balance immediate therapeutic benefits against potential long-term metabolic risks. The study also underscores the need for preventive strategies aimed at preserving or restoring healthy microbiota during and after antibiotic administration, such as targeted probiotics, prebiotics, or dietary interventions designed to promote microbial resilience and diversity.

Moreover, this investigation sheds light on the broader epidemiological trends of the childhood obesity epidemic. While lifestyle and genetic factors indisputably contribute to obesity, the early environmental microbiome represents a modifiable risk factor that has been underappreciated in public health frameworks. By incorporating microbiome-centric perspectives into obesity prevention strategies, there is potential to address the root causes of metabolic dysfunction from a foundational developmental stage, potentially altering the course of disease progression at a population level.

Despite the compelling associations presented, the authors acknowledge several limitations inherent to observational cohort studies. Causality cannot be definitively established without controlled interventional trials. Furthermore, variables such as diet, physical activity, and psychosocial environments, which also influence weight outcomes, may introduce residual confounding. Additionally, the characterization of the microbiome was inferred rather than directly measured in this study, highlighting an important avenue for future research involving metagenomic sequencing and functional microbiome analysis to elucidate specific microbial taxa and molecular pathways implicated in antibiotic-induced obesity risk.

In summary, Heyman and colleagues have provided landmark evidence linking antibiotic exposure in infancy with an increased propensity for overweight and obesity during childhood and adolescence. These findings resonate with a growing body of scientific literature underscoring the significance of early microbial environments in shaping lifelong health. Their work calls for a heightened awareness among clinicians, parents, and policymakers regarding the potential unintended consequences of routine antibiotic use in neonates and infants.

Moving forward, integrating microbiome research into pediatric healthcare could revolutionize approaches to both infection management and metabolic health promotion. Future studies might explore personalized antibiotic regimens, microbiota-friendly therapeutic alternatives, and innovative microbiome restoration techniques that mitigate the obesogenic effects documented. This paradigm shift holds promise for curbing the global childhood obesity crisis by intervening at the earliest stages of human development.

The enduring challenge remains to translate these empirical findings into actionable clinical guidelines and public health policies that safeguard microbiome integrity without compromising infectious disease control. As the field of microbiome science rapidly advances, the integration of multi-omics technologies, longitudinal sampling, and sophisticated computational modeling will be essential to unravel the complex interplay between antibiotics, gut microbiota, and host metabolism.

Ultimately, this study reinforces the concept that the first months of life constitute a formative period in metabolic programming, where external insults such as antibiotic perturbation can leave lasting imprints. Harnessing this knowledge opens new horizons in preventive medicine and paves the way for interventions that promote metabolic resilience from infancy onward.

Subject of Research: The impact of antibiotic exposure during infancy on the development of overweight and obesity in childhood and adolescence.

Article Title: The association between antibiotic use in infancy and overweight during childhood and adolescence: a historical cohort study.

Article References:
Heyman, E., Chodick, G., Fallach, N. et al. The association between antibiotic use in infancy and overweight during childhood and adolescence: a historical cohort study. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01972-6

Image Credits: AI Generated

DOI: 29 November 2025

Keywords: microbiome, gut flora, antibiotics, infancy, overweight, obesity, childhood, adolescence, metabolic programming, dysbiosis, broad-spectrum antibiotics, pediatric health, longitudinal cohort study, obesity epidemic, antibiotic stewardship